GSK plc GSK has announced the approval of the European Commission (EC) for the expanded use of its respiratory syncytial ...

The company's vaccine consists of an mRNA sequence encoding a stabilized prefusion F glycoprotein.

"EC approves GSK’s RSV vaccine for adults aged 50-59 years" was originally created and published by Pharmaceutical Technology ...

Sanofi said on Monday the U.S. Food and Drug Administration has approved a manufacturing line for its and partner AstraZeneca ...

From 1 September, the NHS will vaccinate pregnant women from 28 weeks onward, and adults turning 75, shielding these vulnerable individuals from falling ill this winter. Adults aged 75 to 79 will be ...

With a new production line, Sanofi aims to keep it and partner AstraZeneca’s drug Beyfortus in fully supply this RSV season.

Targeting vaccination programs for respiratory syncytial virus (RSV) to older adults with underlying health conditions is a cost-effective way to reduce disease, according to a new modelling study in ...

With the stock now more than cut in half from its 52-week high, the company recently laid out a plan for its business at its ...

Focuses on ten product approvals through 2027Expects to submit next-generation COVID vaccine for approval in 2024Expects to submit flu/COVID ...

GSK has reported positive results from its phase II trial for an mRNA seasonal influenza vaccine candidate, showing strong immune responses again ...

Delta Air Lines said in an update on Thursday that capacity across the industry was also “moderating” and that its revenue ...

Moderna plans to cut $1.1bn in costs by 2027, pausing and scrapping several R&D programs. See why I think further downside ...